Design of a potent combined pseudopeptide endothelin-a/endothelin-b receptor antagonist, ac-dBhg16-Leu-Asp-IIe-[NMe]IIe-Trp21 (PD 156252): Examination of its pharmacokinetic and spectral properties

Journal of Medicinal Chemistry

Volumn 40, Issue 14, 1997, Pages 2228-2240

  Cody, Wayne L ^a   He, John X ^a   Reily, Michael D ^a   Haleen, Stephen J ^a   Walker, Donnelle M ^a   Reyner, Eric L ^a   Stewart, Barbra H ^a   Doherty, Annette M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; PD 156252; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR DISEASE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN CONFORMATION; RAT;

AMINO ACID SEQUENCE; ANIMALS; DRUG DESIGN; ENDOTHELIN-1; FEMORAL ARTERY; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; OLIGOPEPTIDES; PROTEIN CONFORMATION; PULMONARY ARTERY; RABBITS; RATS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; RENAL CIRCULATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030746698     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970161m     Document Type: Article

References (72)

1. Hickey, K. A.; Rubanyi, G.; Paul, R. J.; Highsmith, R. F. Characterization of a coronary vasoconstrictor produced by endothelial cells in culture. Am. J. Physiol. 1985, 248, C550-C556.
2. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Goto, K.; Masaki, T. A. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (London) 1988, 332, 411-415.
3. Yanagisawa, M.; Inoue, A.; Ishikawa, T.; Kasuya, T.; Kimura, S.; Kumagaye, S.; Nakajima, K.; Watanable, T. X.; Sakabibara, S.; Goto, K.; Masaki, T. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6964-6967.
4. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 2863-2867.
5. Saida, K.; Mitsui, Y.; Ishida, N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression and biological activity. J. Biol. Chem. 1989, 264, 14613-14616.
6. Kloog, T.; Ambar, I.; Sokolovsky, M.; Kochva, E.; Wolberg, Z.; Bdolah, A. Sarafotoxin, a novel vasoconstrictor peptide: Phosphoinositide hydrolysis in rat heart and brain. Science 1988, 242, 268-270.
7. Bdolah, A.; Wolberg, Z.; Fleminger, G.; Kochva, E. SRTX-d, a new native peptide of the endothelin/sarafotoxin family. FEBS Lett. 1989, 251, 1-3.
8. Becker, A.; Dowdle, E. B.; Hechler, U.; Kauser, K.; Donner, P.; Schleuning, W. D. Bibrotoxin, a novel member of the endothelin/ sarafotoxin peptide family, from the venom of the burrowing asp, Atractaspis bibroni. FEBS Lett. 1993, 315, 100-103.
9. Doherty, A. M. Endothelin: A new challenge. J. Med. Chem. 1992, 35, 1493-1508.
10. Huggins, J. P.; Pelton, J. T.; Miller, R. C. The structure and specificity of endothelin receptors: Their importance in physiology and medicine. Pharmacol. Ther. 1993, 59, 55-123.
11. Cheng, X. M.; Nikam, S. S.; Doherty, A. M. Development of agents to modulate the effects of endothelin. Cur. Med. Chem. 1995, 1, 271-312.
12. Cody, W. L.; Doherty, A. M. Development of agents to modulate the effects of endothelin. Biopolymers (Pept. Sci.) 1995, 37, 89-104.
13. Arai, H.; Hori, T.; Aramori, I.; Ohkubo, H.; Nakanishi, S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature (London) 1990, 348, 730-732.
14. Sakurai, T.; Yanagisawa, M.; Takuwa, Y.; Miyazaki, H.; Kimura, S.; Goto, K.; Masaki, T. Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature (London) 1990, 348, 732-735.
15. Sakamoto, A.; Yanagisawa, M.; Sakurai, T.; Takuwa, Y.; Yanagisawa, H.; Masaki, T. Cloning and functional expression of human cDNA for ETB endothelin receptor. Biochem. Biophys. Res. Commun. 1991, 178, 656-663.
16. Hosoda, K.; Nakao, K.; Arai, H.; Suga, S.; Ogawa, Y.; Mukoyama, M.; Shirakami, G.; Saito, T.; Nakanishi, S.; Imura, H. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett. 1991, 287, 23-26.
17. Williams, D. L.; Jones, K. L.; Pettibone, D. L.; Lis, E. V.; Clineschmidt, B. V. Sarafotoxin S6c: An agonist which distinguishes between endothelin receptor subtypes. Biochem. Biophys. Res. Commun. 1991, 175, 556-561.
18. Takayanagi, R.; Kitazumi, K.; Takasaki, C.; Ohnaka, K.; Aimoto, S.; Tasaka, K.; Ohashi, M.; Nawata, H. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS. Lett. 1991, 282, 103-106.
19. 1,3,11,15]Endothelin-1 analogs with ETB agonist activity. Biochem. Biophys. Res. Commun. 1991, 179, 286-292.
20. Panek, R. L.; Major, T. C.; Hingorani, G. P.; Doherty, A. M.; Taylor, D. G.; Rapundalo, S. T. Endothelin and structurally related analogs distinguish between receptor subtypes. Biochem. Biophys. Res. Commun. 1992, 183, 566-571.
21. Sudjarwo, S. A.; Hori, M.; Takai, M.; Urade, Y.; Okada, T.; Karaki, H. A novel type of endothelin B receptor mediating contraction in swine pulmonary vein. Life Sci. 1993, 53, 431-437.
22. Warner, T. D.; Allcock, G. H.; Corder, R.; Vane, J. R. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br. J. Pharmacol. 1993, 110, 777-782.
23. Reynolds, E. E.; Hwang, O.; Flynn, M. A.; Welch, K. M.; Cody, W. L.; Steinbaugh, B.; He, J. X.; Chung, F. Z.; Doherty, A. M. Pharmcological differences between rat and human endothelin B receptors. Biochem. Biophys. Res. Commun. 1995, 209, 506-512.
24. Doherty, A. M.; Cody, W. L.; Leitz, N. L.; DePue, P. L.; Taylor, M. D.; Rapundalo, S. T.; Hingorani, G. P.; Major, T. C.; Panek, R. L.; Taylor, D. G. Structure-activity studies of the C-terminal region of the endothelins and the sarafotoxins. J. Cardiovasc. Pharmacol. 1991, 17 (Suppl. 7), S59-S61.
25. Cody, W. L.; Doherty, A. M.; He, J. X.; DePue, P. L.; Rapundalo, S. T.; Hingorani, G. A.; Major, T. C.; Panek, R. L.; Dudley, D. T.; Haleen, S. J.; LaDouceur, D.; Hill, K. E.; Flynn, M. A.; Reynolds, E. E. Design of a functional hexapeptide antagonist of endothelin. J. Med. Chem. 1992, 35, 3301-3303.
26. 16]. Bioorg. Med. Chem. Lett. 1993, 3, 497-502.
27. Doherty, A. M.; Cody, W. L.; DePue, P. L.; He, J. X.; Waite, L. A.; Leonard, D. M.; Leitz, N. L.; Dudley, D. T.; Rapundalo, S. T.; Hingorani, G. P.; Haleen, S. J.; LaDouceur, D. M.; Hill, K. E.; Flynn, M. A.; Reynolds, E. E. Structure-activity relationships of C-terminal endothelin hexapeptide antagonists. J. Med. Chem. 1993, 36, 2585-2594.
28. B receptor subtype selective antagonists. In Peptides, Chemistry, Structure and Biology: Proceedings of the Thirteenth American Peptide Symposium; Hodges, R. S., Smith, J. A., Eds.; ESCOM Science: Leiden, The Netherlands, 1994; pp 598-600.
29. 21: Development of endothelin-B rececptor selective antagonists. J. Med. Chem. 1995, 38, 2809-2819.
30. Cody, W. L.; Doherty, A. M.; He, J. X.; Topliss, J. G.; Haleen, S. J.; LaDouceur, D.; Flynn, M. A.; Hill, K. E.; Reynolds, E. E. Structure-activity relationships in the C-terminus of endothelin-1 (ET-1): The discovery of potent antagonists. In Peptides 1992: Proceedings of the Twenty-Second European American Peptide Symposium; Schneider, C. H., Eberle, A. N., Eds.; ESCOM Science: Leiden, The Netherlands, 1993; pp 687-688.
31. Cody, W. L.; Doherty, A. M.; He, J. X.; DePue, P. L.; Waite, L. A.; Topliss, J. G.; Haleen, S. J.; LaDouceur, D.; Flynn, M. A.; Hill, K. E.; Reynolds, E. E. The rational design of a highly potent combined ETA and ETB receptor antagonist (PD 145065) and related analogues. Med. Chem. Res. 1993, 3, 154-162.
32. Doherty, A. M.; Cody, W. L.; He, J. X.; DePue, P. L.; Cheng, X.-M.; Welch, K. M.; Flynn, M. A.; Reynolds, E. E.; LaDouceur, D. M.; Davis, L. S.; Keiser, J. A.; Haleen, S. J. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J. Cardiovasc. Pharmacol. 1993, 22 (Suppl. 8), S98-S102.
33. Cody, W. L.; He, J. X.; Doherty, A. M.; DePue, P. L.; Kaltenbronn, J. S.; Reisdorph, B. R.; Walker, D. M.; Welch, K. M.; Haleen, S. J.; Reynolds, E. E.; Tse, E.; Reyner, E. L.; Stewart, B. H. The design of potent hexapeptide endothelin antagonists stable to proteolysis. In Peptides 1994: Proceedings of the Twenty-Third European Peptide Symposium; Maia, H. L. S., Ed.; ESCOM Science: Leiden, The Netherlands, 1993; pp 38-39.
34. Stewart, B. H.; Reyner, E. L.; Tse, E.; Hayes, R. N.; Werness, S.; He, J. X.; Cody, W. L.; Doherty, A. M. In vitro assessment of oral delivery for hexapeptide endothelin antagonists. Life Sci. 1996, 58, 971-982.
35. Kessler, H.; Knot, R. K.; Schmitt, W. Conformational analysis of peptides: Application to drug design. In NMR Drug Design; Craik, D. J., Ed.; CRC Press: Boca Raton, FL, 1996; pp 215-244.
36. Kessler, H.; Köck, M.; Wein, T.; Gehrke, M. Reinvestigation of the conformation of cyclosporin A in chloroform. Helv. Chim. Acta 1990, 73, 1818-1832.
37. Kessler, H.; Haessner, R.; Schüler, W. Structure of rapamycin: An NMR and molecular-dynamics investigation. Helv. Chim. Acta 1993, 76, 117-130.
38. 13. Can. J. Chem. 1978, 56, 2491-2492.
39. 5]enkephalin, a highly potent, δ-opioid receptor selective compound: Comparisons with proposed solution conformations. J. Am. Chem. Soc. 1994, 116, 7523-7531
40. Melacini, G.; Zhu, Q.; Goodman, M. Multiconformational NMR analysis of sandostatin (octreotide): Equilibrium between β-sheet and helical structures. Biochemistry 1997. 36, 1233-1241.
41. Wüthrich, K. NMR of Proteins and Nucleic Acids; J. Wiley and Sons: New York, 1984.
42. Reily, M. D.; Thanabal, V.; Omecinsky, D. O. Structure-induced carbon-13 chemical shifts: A sensitive measure of transient localized secondary structure in peptides. J. Am. Chem. Soc. 1992, 114, 6251-6252.
43. Stewart, J. M.; Young, J. D. Solid Phase Synthesis, 2nd ed.; Pierce Chemical Co.: Rockford, IL, 1984.
44. Bodansky, M.; Bodansky, A. The Practice of Peptide Synthesis; Springer-Verlag: Berlin, Germany, 1984.
45. Mitchell, A. R.; Erickson, B. W.; Ryabtsev, M. N.; Hodges, R. S.; Merrifield, R. B. Tert-butoxycarbonylaminoacyl-4-(oxymethyl)-phenylacetamidomethyl-resin, a more acid-resistant support for solide-phase peptide synthesis. J. Am. Chem. Soc. 1976, 98, 7357-7562.
46. Chen, H. G.; Beylin, V. G.; Leja, B.; Goel, O. P. Chiral synthesis of D-and L-3,3-diphenylalanine (DIP), unusual I-amino acids for peptides of biological interest. Tetrahedron Lett. 1992, 33, 3293-3296.
47. Beylin, V. G.; Chen, H. G.; Dunbar, J. B.; Goel, O. P.; Harter, W.; Marlett, M.; Topliss, J. G. Cyclic derivatives of 3,3-diphenylalanine (Dip). II. Novel I-amino acids for peptides of biological interest. Tetrahedron Lett. 1992, 34, 953-956.
48. Knittel, J. J.; He, J. X. Synthesis and resolution of novel 3′-substituted phenylalanine amides. Pept. Res. 1990, 3, 176-181.
49. 2NH peptide bond isostere. Peptides 1987, 8, 119-121.
50. 2NH] pseudopeptide analogs of a highly potent somatostatin octapeptide. J. Med. Chem. 1987, 30, 1162-1166.
51. Fehrentz, J. A.; Castro, B. An efficient synthesis of optically active α-(t-butoxycarbonylamino)-aldehydes from α-amino acids. Synthesis 1983, 676-678.
52. Kaljuste, K.; Unden, A. New method for the synthesis of N-methyl amino acids containing peptides by reductive methylation of amino groups on the solid phase. Int. J. Pept. Protein Res. 1993, 42, 118-124.
53. Freidinger, R. M.; Hinkle, J. S.; Perlow, D. S. Synthesis of 9-fluorenylmethyloxycarbonyl-protected N-alkyl amino acids by reduction of oxazolidinones. J. Org. Chem. 1983, 48, 77-81.
54. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
55. Woodley, J. F. Enzymic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 1994, 11, 61-95.
56. Cody, W. L.; He, J. X.; Flynn, M. A.; Welch, K. M.; Reynolds, E. E.; Doherty, A. M. Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co., unpublished results.
57. Stewart, B. H.; Reyner, E. L.; Tse, E.; Hayes, R. N.; Cody, W. L.; Doherty, A. M. In vitro assessment of oral delivery for hexapeptide endothelin antagonists using stability in intestinal perfusate and Caco-2 permeability. Pharm. Res. 1994, 11, S-257.
58. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 1991, 175, 880-885.
59. Hidalgo, I. J.; Raub, R. J.; Borchardt, R. T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 96, 736-749.
60. Pinto, M.; Robine-Leon, S.; Appay, M. D.; Kedinger, M.; Triadou, N.; Dussaulx, E.; Lacrois, B.; Simon-Assmann, P.; Haffen, K.; Fogh, J.; Zweibaum, A. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 1983, 47, 232-330.
61. B endothelin receptor antagonist in the presence of dodecylphosphocholine micelles. Biochemistry 1997, in press.
62. Szilágyi, L. Chemical shifts in proteins come of age. Prog. Nucl. Magn. Reson. Spectrosc. 1995, 27, 325-443.
63. 15N Random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest neighbor effects. J. Biomol. NMR 1995, 5, 67-81.
64. Braunschweiler, L.; Ernst, R. R. Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy. J. Magn. Reson. 1983, 53, 521-528.
65. Rance, M.; Soerensen, O. W.; Bodenhausen, G.; Wagner, G.; Ernst, R. R.; Wüthrich, K. Improved spectral resolution in COSY proton NMR spectra of proteins via double quantum filtering. Biochem. Biophys. Res Commun. 1983, 117, 479-485.
66. Bothner-By, A. A.; Stephens, R. L.; Lee, J.; Warren, C. D.; Jeanloz, R. W. J. Am. Chem. Soc. 1984, 106, 811-813.
67. Bax, A.; Davis, D. G. Practical aspects of two-dimensional transverse NOE spectroscopy. J. Magn. Reson. 1985, 65, 355-360.
68. Kumar, A.; Ernst, R. R.; Wüthrich, K. A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. Biochem. Biophys. Res. Commun. 1980, 95, 1-6.
69. Marion, D.; Wüthrich, K. Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of proton-proton spin-spin coupling constants in proteins. Biochem. Biophys. Res. Commun. 1983, 113, 967-974.
70. Reily, M. D.; Thanabal, V.; Adams, M. E. The solution structure of ω-Aga-IVB, a P-type calcium channel antagonist from venom of the funnel web spider, Agelenopsis aperta. J. Biomol. NMR 1995, 5, 122-132.
71. 13C chemical shifts of amino acids in aqueous solution containing organic solvents: Application to the secondary struture characterization of peptides in aqueous trifluoroethanol solution. J. Biomol. NMR 1994, 4, 47-59.
72. Howarth, O. W.; Lilley, D. M. J. Carbon-13 NMR of peptides and proteins. Prog. Nucl. Magn. Reson. Spectrosc. 1978, 12, 1-40.